XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

Stock Information for XORTX Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XORTX Therapeutics Inc.

XORTX Announces Results of Annual and Special Meeting of Shareholders
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
XORTX Announces Presentation at American Society of Nephrology - Kidney Week 2024
XORTX to Present at BIO International Convention 2024
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.